Medtronic expands cSDH treatment options with US FDA clearance of Aristotle Mini guidewire
Article excerpt
Highlighted: the sentence this signal was extracted from
Medtronic has announced the launch of the Aristotle Mini guidewire following US Food and Drug Administration (FDA) 510(k) clearance in August this year. As stated in a press release, this clearance follows the recent US FDA approval of the Onyx 12 liquid embolic system and further expands Medtronic's offerings for the treatment of chronic subdural haematoma (cSDH), adding a lower-profile option to the Aristotle guidewire portfolio that is designed to help physicians reliably reach the anatomy they need to treat. For procedures like middle meningeal artery (MMA) embolisation - during which physicians often need to navigate small, distal vessels before delivering therapy - Aristotle Mini is intended to support access to these anatomies, bringing lower-profile navigation together with embolic therapy. Built on Medtronic's proprietary microfabrication technology, Aristotle Mini seeks to provide the structural integrity, steerability and control physicians need, the company claims. The newly launched device is compatible with 0.013-inch inner diameter microcatheter workflows, and complements Medtronic neurovascular technologies like Marathon and Apollo microcatheters as well as Onyx liquid embolic systems. "As the burden of cSDH continues to grow, physicians need access to a range of technologies that help them treat increasingly complex anatomy," said Linnea Burman, senior vice...
Keep reading with a free account
The rest of this article, and every signal for Medtronic, is in your free account.
